|drug2858||Respiratory tele-rehabilitation program (TRR). Wiki||1.00|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
|D018352||Coronavirus Infections NIH||0.03|
There is one clinical trial.
Some patients with COVID-19 have sequelae after the acute phase of infection. These sequelae can be physical (dyspnea, exercise intolerance, abnormal fatigue) but also psychic (anxiety, depression). Systemic sequelae have also been observed in pulmonary, cardiac, hepatic, renal, nervous or immune systems. Respiratory rehabilitation (RR) is indicated in these patients to help their complete recovery without sequelae. These patients' arrival and sanitary constraints imposed by COVID-19 changed the organization of Health Care Centers (HCC). Risk of contagiousness after the acute phase of infection still exists. Consequently, patients must respect a quarantine time on their arrival in HCC and then have no contact with other HCC patients to respect the barrier rules and social distancing measures. HCC accommodation capacities are reduced and this is to the detriment of patients with chronic diseases for whom RR is essential. Certain HCCs saturation can also be responsible for a non-proposal of RR in the care pathway of patients after COVID-19. To cope with the new constraints imposed by Covid-19 pandemic, telemedicine is being developed in the affected industrial countries. Some SRH physicians are starting to offer post-COVID-19 patients the possibility of carrying out a tele-rehabilitation program (TRR). Such a telemedicine program has been validated for people with respiratory failure. It allows the patient to follow his care program without leaving his home and it does not require the visit from a health professional. In addition to reducing the inflow of post COVID-19 patients in HCC, it allows fragile patients to respect social distancing. It could also contain virus spread virus on the territory by reducing patient movements. When choosing between RR and TRR, the clinician must ask himself two questions. Is TRR as efficient as RR for post-COVID-19 patients? Is there a profile of patients for whom either method gives better results? This study proposes to evaluate both methods: a 4-week TRR program vs a conventional RR program in post COVID-19 patients with sequelae. If the hypothesis that both methods have similar effects is verified, this would allow the generalization of the prescription of TRR. The benefits will be individual with greater access to respiratory rehabilitation for post COVID-19 patients. There will also be collective public health benefits by maintaining sufficient access to HCC for patients with chronic diseases.
Description: The 6-min walk test (6 MWT) measures the distance that a patient can quickly walk on a flat, hard surface in a period of 6 minutes (the 6MWD). (ATS Statement: Guidelines for the Six-Minute Walk Test, Am J Respir Crit Care Med, 2002)Measure: Distance walked in the 6-min walk test (6 MWT). Time: 8 weeks
Description: All 1-min STS tests are performed according to a standardized protocol by trained study staff. A standard chair is used (height 46-48 cm) with a flat seat and no armrests, stabilized against a wall. Patients are asked to sit with their legs hip-width apart and flexed to 90°, with their hands stationary on the hips without using the hands or arms to assist movement. They are instructed to stand completely straight and touch the chair with their bottom when sitting, but they need not sit fully back on the chair. Patients are asked to perform as many repetitions as possible in 1 min, and after 45 s are told "you have 15 s left until the test is over". (Crook S, et al. Eur Respir J 2017)Measure: Number of repetitions performed in a 1-min Sit-to-Stand (STS) test Time: 8 weeks
Description: The mMRC dyspnea scale allows to assess degree of baseline functional disability due to dyspnea. (Vestbo J, et al. Am J Respir Crit Care Med, 2013)Measure: Dyspnea evaluated by the modified Medical Research Council (mMRC) Time: 8 weeks
Description: Multidimensional Fatigue Inventory (MFI-20) is a 20-item self-report instrument which covers the following dimensions: general fatigue, physical fatigue, reduced activity, reduced motivation, and mental fatigue (Schwarz, et al. Onkologie, 2003)Measure: Fatigue evaluated by the Multidimensional Fatigue Inventory (MFI-20) Time: 8 weeks
Description: The Hospital Anxiety and Depression Scale (HADS) can be useful tools for identifying potential cases of anxiety and depression (Roberge P, et al. J Affect Disord.2013)Measure: Anxiety and Depression evaluated by the Hospital Anxiety and Depression Scale (HADS) Time: 8 weeks
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports